Press Releases

ExCellThera to present at 2019 Cell & Gene Meeting on the Mesa

MONTREAL, September 11, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that Guy Sauvageau, President and CEO, will present a company update at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California. ExCellThera’s lead technology, ECT-001, is a combination of a small molecule and an optimized culture system. The technology, capable of expanding stem […]

Read more »


ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center

MONTREAL, MAY 7, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has entered into a manufacturing and collaboration agreement with Comprehensive Cell Solutions (CCS), a division of New York Blood Center (NYBC) for the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001. The agreement provides ExCellThera access to New York Blood Center’s cGMP clean room manufacturing facilities in […]

Read more »


ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation

MONTREAL, April 23, 2019 – ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment […]

Read more »


ExCellThera announces clearance by FDA and Health Canada for ECT-001 in new clinical trials in United States and Canada for the treatment of leukemia

MONTREAL, March 25, 2019 – ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that its lead technology, ECT-001, will be used as part of two new clinical trials in patients with high-risk leukemia. The announcement follows the recent clearance of the company’s Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) and of a clinical trial application by Health Canada, in […]

Read more »


ExCellThera receives FDA orphan drug designation for ECT-001 for the prevention of graft-versus-host disease

MONTREAL, December 17, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted the ExCellThera’s lead solution, ECT-001, orphan drug designation for the prevention of graft-versus-host-disease (GvHD). ECT-001 uses a proprietary small molecule and an optimized culture system to expand therapeutic stem and immune cells and is being evaluated in several clinical trials. Orphan drug designation is […]

Read more »


ExCellThera announces results of clinical trial using ECT-001 for blood cancers

MONTREAL, December 4, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced results from the Phase I/II clinical trial using its lead technology, ECT-001, for allogeneic stem cell transplant. The results of the study were presented at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego and demonstrated conclusively that blood cells expanded for seven days with ECT-001 are effective at providing substantial […]

Read more »


ExCellThera announces clinical trial results using ECT-001 to be presented at ASH 2018 annual meeting

MONTREAL, November 8, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced that results from the Phase I/II clinical trial using its lead technology, ECT-001, for allogeneic stem cell transplant, will be presented at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego. Details of the presentation are as follows: Date & Time: Monday, December 3, 2018; 6:00-8:00 p.m. PT Title: Single UM171 […]

Read more »


Final patient receives treatment in stem cell clinical trial for severe blood cancers

MONTREAL, June 27, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today the close of its initial, 25-patient clinical trial for its lead technology, ECT-001. The final patient in this phase of the study, led by Dr. Sandra Cohen at the Maisonneuve-Rosemont Hospital in Montreal, received treatment late last week. Preliminary findings from the trial have shown that stem cells expanded with ECT-001 are both safe and […]

Read more »


ECT-001 is basis of new clinical trial for multiple myeloma

(le français suit) MONTREAL, May 14, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today that its lead platform, ECT-001, will be used as part of a new Phase I/II clinical trial in patients with multiple myeloma. The study will enroll up to 20 high-risk, multiple myeloma patients from the Hôpital Maisonneuve-Rosemont in Montreal, Canada. ECT-001 will be used in this trial to expand blood stem cells […]

Read more »


ExCellThera announces appointment of Chief Financial and Legal Officer

(le français suit) MONTREAL, March 22, 2018 – ExCellThera Inc. announced today the appointment of David Millette as Chief Financial and Legal Officer effective April 3, 2018. Mr. Millette combines a solid background in finance and law, having practised in the areas of accounting, finance and management consulting with a leading firm of chartered professional accountants for several years, and in the areas of corporate and securities law, financings and business acquisitions and sales for over a decade, including several […]

Read more »